Literature DB >> 22776989

Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.

Miguel Serrano1, Pedro Lage, Sara Belga, Bruno Filipe, Inês Francisco, Paula Rodrigues, Ricardo Fonseca, Paula Chaves, Isabel Claro, Cristina Albuquerque, António Dias Pereira.   

Abstract

In 1997 Bethesda Guidelines (BG) were established and in 2004 those criteria were revised (RBG), with the main goal of selecting colorectal cancers (CRC) that should be subjected to microsatellite instability (MSI) testing. High microsatellite instability (MSI-H) is an intermediate marker for mutational analysis of the mismatch repair (MMR) genes involved in the genesis of Lynch Syndrome (LS). We aimed to evaluate and compare BG/RBG in the detection of MSI-H and subsequent identification of pathogenic MMR genes mutations. We included 174 patients with CRC and indication for MSI analysis according to BG or RBG. MSI testing was performed with the Bethesda markers and mutational analysis of MLH1, MSH2 and MSH6 genes undertaken with DGGE, MLPA and direct sequencing. One hundred fourteen of 174 patients (65.5 %) fulfilled BG and all of them RBG. With the BG, MSI-H was detected in 37/114 (32.5 %) CRCs and mutational analysis was positive in 14/37 (37.8 %) patients. The RBG led to detection of MSI-H in 49/174 (28.2 %) of the CRCs, having the mutational analysis been positive in 16/49 (32.7 %) patients. We could identify 14/114 (12.3 %) new cases of LS, through BG and 16/174 (9.2 %) via RBG. BG presented a similar overall percentage for the detection of MSI-H and mutations when compared with RBG. RBG implicated the analysis of more patients, though they gave rise to detection of two additional LS cases. This difference has a significant impact on the establishment of preventive measures, mainly for CRC, in all the mutation-carriers belonging to these families.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776989     DOI: 10.1007/s10689-012-9550-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  43 in total

1.  DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1 and hMSH2.

Authors:  E Holinski-Feder; Y Müller-Koch; W Friedl; G Moeslein; G Keller; J Plaschke; W Ballhausen; M Gross; K Baldwin-Jedele; M Jungck; E Mangold; H Vogelsang; H K Schackert; P Lohsea; J Murken; T Meitinger
Journal:  J Biochem Biophys Methods       Date:  2001-01-30

2.  Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness.

Authors:  Carolina M Reyes; Brian A Allen; Jonathan P Terdiman; Leslie S Wilson
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

3.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.

Authors:  F Quehenberger; H F A Vasen; H C van Houwelingen
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

4.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Prediction of MLH1 and MSH2 mutations in Lynch syndrome.

Authors:  Judith Balmaña; David H Stockwell; Ewout W Steyerberg; Elena M Stoffel; Amie M Deffenbaugh; Julia E Reid; Brian Ward; Thomas Scholl; Brant Hendrickson; John Tazelaar; Lynn Anne Burbidge; Sapna Syngal
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

6.  Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.

Authors:  Christophe Tresallet; Antoine Brouquet; Catherine Julié; Alain Beauchet; Céline Vallot; Fabrice Ménégaux; Emmanuel Mitry; François Radvanyi; Robert Malafosse; Philippe Rougier; Bernard Nordlinger; Pierre Laurent-Puig; Catherine Boileau; Jean-François Emile; Christine Muti; Christophe Penna; Hélène Hofmann-Radvanyi
Journal:  Int J Cancer       Date:  2011-07-25       Impact factor: 7.396

7.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

8.  Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients.

Authors:  J Balmaña; F Balaguer; S Castellví-Bel; E W Steyerberg; M Andreu; X Llor; R Jover; A Castells; S Syngal
Journal:  J Med Genet       Date:  2008-06-25       Impact factor: 6.318

9.  Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients.

Authors:  L A Aaltonen; P Peltomäki; J P Mecklin; H Järvinen; J R Jass; J S Green; H T Lynch; P Watson; G Tallqvist; M Juhola
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  7 in total

Review 1.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

2.  Proficiency of DNA repair genes and microsatellite instability in operated colorectal cancer patients with clinical suspicion of lynch syndrome.

Authors:  Isabella Nicácio de Freitas; Fábio Guilherm Caserta Maryssael de Campos; Venâncio Avancini Ferreira Alves; Juliana Magalhães Cavalcante; Dirce Carraro; Renata de Almeida Coudry; Márcio Augusto Diniz; Sérgio Carlos Nahas; Ulysses Ribeiro
Journal:  J Gastrointest Oncol       Date:  2015-12

3.  Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability.

Authors:  Arfaoui Toumi Amira; Trabelsi Mouna; Blel Ahlem; Aloui Raoudha; Ben Hmida Majid; Hamza Amel; Zermani Rachida; Kourdaa Nadia
Journal:  Tumour Biol       Date:  2014-03-19

4.  Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.

Authors:  Felipe Carneiro da Silva; José Roberto de Oliveira Ferreira; Giovana Tardin Torrezan; Márcia Cristina Pena Figueiredo; Érika Maria Monteiro Santos; Wilson Toshihiko Nakagawa; Rafael Canfield Brianese; Ligia Petrolini de Oliveira; Maria Dirlei Begnani; Samuel Aguiar-Junior; Benedito Mauro Rossi; Fábio de Oliveira Ferreira; Dirce Maria Carraro
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

5.  Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population.

Authors:  Wen-Yue Yan; Jing Hu; Li Xie; Lei Cheng; Mi Yang; Li Li; Jiong Shi; Bao-Rui Liu; Xiao-Ping Qian
Journal:  Onco Targets Ther       Date:  2016-12-08       Impact factor: 4.147

Review 6.  Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer.

Authors:  Mehrdad Zeinalian; Morteza Hashemzadeh-Chaleshtori; Rasoul Salehi; Mohammad Hassan Emami
Journal:  Adv Biomed Res       Date:  2018-02-16

7.  Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors.

Authors:  Lena Hieggelke; Carina Heydt; Roberta Castiglione; Jan Rehker; Sabine Merkelbach-Bruse; Cristina Riobello; José Luis Llorente; Mario A Hermsen; Reinhard Buettner
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.